Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Evaluating the clinical utility of soluble interleukin-2 receptor testing in diagnosing adult HLH: A single-center retrospective study

McKailey Salard, Raneem Khattab, Durga Bandi et al. Nov 03, 2025 pp. 4767-4767 10.1182/blood-2025-4767

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by uncontro...

DNA methylation markers assessed at birth are associated with future development of pediatric acute lymphoblastic leukemia

Eric Nickels, Anmol Pardeshi, Joseph Wiemels Nov 03, 2025 pp. 331-331 10.1182/blood-2025-331

Abstract The underlying etiologic development of pediatric acute lymphoblastic leukemias (ALL) is not fully understood.While clinical outcom...

Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohort

Lin-Pierre Zhao, Céline Berthon, Lauren Fenwarth et al. Nov 03, 2025 pp. 454-454 10.1182/blood-2025-454

Abstract Background: In older patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML), treatment options have expanded signifi...

Single-cell and spatial transcriptomics analyses decipher malignant B cell heterogeneity and immunosuppressive microenvironment in primary central nervous system lymphoma

Cong Wang, Tiange Lu, Xiangrong Zheng et al. Nov 03, 2025 pp. 1762-1762 10.1182/blood-2025-1762

Abstract Over 95% of primary central nervous system lymphoma (PCNSL) cases are histologically classified as diffuse large B-cell lymphoma (D...

Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement

Wu Shishuang, wenjun ji, Jiayi Ren et al. Nov 03, 2025 pp. 1209-1209 10.1182/blood-2025-1209

Abstract Hemophagocytic lymphohistiocytosis (HLH) constitutes a life-threatening hyperinflammatory state characterized by immune dysregulati...

Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden

Bart Przychodzen, Sandra Smieszek Nov 03, 2025 pp. 7283-7283 10.1182/blood-2025-7283

Abstract Myeloproliferative disorders are clonal hematopoietic stem cell malignancies with cytokine independency or hypersensitivity. Due to...

Clinical safety of oral administration of hbi-002 carbon monoxide drug product in healthy subjects and individuals with sickle cell disease

Fernando Diaz, Carlos Osorio Montero, Edward Gomperts et al. Nov 03, 2025 pp. 615-615 10.1182/blood-2025-615

Abstract HBI-002 is a liquid drug product containing carbon monoxide (CO) intended for oral administration with target peak CO-hemoglobin (C...

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome

Lorena Caulkins, Stephen Spurgeon Nov 03, 2025 pp. 8247-8247 10.1182/blood-2025-8247

Abstract Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a serious and potentially fatal toxicity associated w...

Lysophosphatidylcholine-induced macrophage polarization imbalance and functional dysregulation in immune thrombocytopenia

Shuwen Wang, Nan Jiang, Jun Peng Nov 03, 2025 pp. 1244-1244 10.1182/blood-2025-1244

Abstract Introduction Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by reduced platelet counts and increased...

IHP-102 compound decreases the adhesion of sickle cell disease RBCs to acutely activated endothelial cells in biochip labs endothelial-on-a-chip assay

Chiara Federici, Samantha Braxton, Ahmad Dakhlallah et al. Nov 03, 2025 pp. 4708-4708 10.1182/blood-2025-4708

Abstract Background: The adhesion of red blood cells (RBCs) to the vasculature constitutes a pathophysiological manifestation of Sickle Cell...

Genetic and clinical profiles of chronic lymphocytic leukemia in Thailand: Nationwide insights from the thai lymphoma study group

Ornnicha Sathitakorn, Sirorat Kobbuaklee, Chantiya Chanswangphuwana et al. Nov 03, 2025 pp. 2122-2122 10.1182/blood-2025-2122

Abstract Introduction: Genomic studies have illuminated the complex clonal heterogeneity of chronic lymphocytic leukemia (CLL) offering crit...

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study

Wei Guo, Yangzhi Zhao, Jia Li et al. Nov 03, 2025 pp. 1921-1921 10.1182/blood-2025-1921

Abstract Background: Treatment of non-Hodgkin lymphoma (NHL) with high tumor burden remains challenging, and treatment with R-CHOP in this p...

Synergistic vulnerability of aggressive B-cell lymphoma to combined MCL-1 inhibition and CAR-T cell therapy

Jing Gao, Xiaohong Zhao, Qing Yin et al. Nov 03, 2025 pp. 7083-7083 10.1182/blood-2025-7083

Abstract Aggressive B-cell lymphomas are often driven by MYC overexpression, which contributes to their rapid progression, therapeutic resis...

Impact of different Sf3b1 mutations on hematopoietic function and erythropoiesis

Brittnie-lee Duffus, Cyrielle Holuka, John Harper et al. Nov 03, 2025 pp. 5620-5620 10.1182/blood-2025-5620

Abstract Myelodysplastic syndrome (MDS) is a group of hematological disorders defined by clonal expansion of hematopoietic stem cells (HSCs)...

Enumeration of plasma cells in the bone marrow of persons with multiple myeloma: Correlation between conventional panoptical microscopy of the aspirate, flow cytometry and bone marrow biopsy.

Miguel Gómez Cabrera, Lidia Alberto López, Sofía Chávez Martínez et al. Nov 03, 2025 pp. 7537-7537 10.1182/blood-2025-7537

Abstract Background: The diagnosis of multiple myeloma (MM) needs the enumeration of the plasma cells (PC) in the bone marrow (BM); the perc...

Early Results of comparison of low-dose generic dasatinib (50 MG/Day) versus imatinib (400 MG/Day) in newly diagnosed chronic Phase chronic myeloid leukemia: Real-world evidence from a single-center, randomized controlled study from India

Shivangi Sharma, Priyadarshini Peram, S Venkata Kiran et al. Nov 03, 2025 pp. 5562-5562 10.1182/blood-2025-5562

Abstract Background:Chronic myeloid leukemia is one of the most prevalent leukemias in the adult Indian population. Imatinib remains the TKI...

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Dong Hyun Kim, Sanyeowool An, Ka-Won Kang et al. Nov 03, 2025 pp. 3692-3692 10.1182/blood-2025-3692

Abstract Introduction Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of non-Hodgkin lymphoma with poor prog...

Pre-chemotherapy microbiome dysbiosis in hematologic malignancies

Chepsy Philip, Anjali Jacob, Giriprasad Venugopal et al. Nov 03, 2025 pp. 6125-6125 10.1182/blood-2025-6125

Abstract Background: The human gut microbiome plays a pivotal role in health and disease, influencing immunity, metabolism, and disease susc...

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Junyu Wang, Bo Jiao, Tuantuan Gui et al. Nov 03, 2025 pp. 3362-3362 10.1182/blood-2025-3362

Abstract Acute lymphoblastic leukemia (ALL) is a highly heterogeneous hematologic malignancy, with pathogenesis closely linked to metabolic...

Genomic landscape of mycosis fungoides

Fadzai Chinyengetere, Leonardo P. A. Biral, Veronica Russell et al. Nov 03, 2025 pp. 7062-7062 10.1182/blood-2025-7062

Abstract Introduction: Cutaneous T-cell lymphomas (CTCLs) are a rare, clinically heterogenous group of extranodal lymphomas that arise from...

Idiopathic multicentric castleman disease - tafro: A potentially curable disease?

Lu Zhang, Jiaying Ge, Siyuan Li et al. Nov 03, 2025 pp. 1230-1230 10.1182/blood-2025-1230

Abstract Idiopathic multicentric Castleman disease (iMCD) is a group of rare and sometimes life-threatening hematological disorders.The Cast...

Iron overload is prevalent, likely underdiagnosed and undertreated in sickle cell disease: A real-world report from the ASH research collaborative

Samuel Wilson, Chunyan Liu, Nicole Herrera et al. Nov 03, 2025 pp. 2667-2667 10.1182/blood-2025-2667

Abstract Introduction Despite the utility of red blood cell transfusion therapy for managing the acute and chronic compl...

Nationwide interpretable point‑of‑care score for CLL/SLL in‑hospital mortality with temporal validation and triage net benefit (NIS 2016–2022)

Xiaoyi Zhang, Abhishek Kumar, Toru Yoshino et al. Nov 03, 2025 pp. 7927-7927 10.1182/blood-2025-7927

Abstract Background Inpatient mortality in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) approaches 6%, yet clinicians l...

Rehabilitation needs and predictors of functional outcomes following CAR T-cell therapy in lymphoma and multiple myeloma

Hanan Alharthy, Abdulaziz Abu Haimed, Haroon Ahmad et al. Nov 03, 2025 pp. 6289-6289 10.1182/blood-2025-6289

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy is increasingly used for relapsed/refractory non-Hodgkin lymphoma (NHL)...

Targeted online education in obstetric hematology significantly improves resident knowledge and addresses a critical training gap

Tabea Sutter, Heather Vandermeulen, Nadine Shehata et al. Nov 03, 2025 pp. 4640-4640 10.1182/blood-2025-4640

Abstract Introduction The care of pregnant individuals with hematologic disorders requires the expertise of two distinct medical specialties...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page